← Back to Home

How Can Cell and Gene Therapies Ensure Biological Activity in Every Batch? FDA Updates Potency Assurance Guidance

From raw materials and manufacturing to delivery to patients, a therapy’s biological activity can be affected at every stage. The FDA’s final guidance broadens the scope of quality management, emphasizing that testing before release alone is insufficient to ensure potency.

By SURL BioNews

Does a batch of cell or gene therapy that passes release testing still retain its expected biological activity when it reaches the patient? For products with short shelf lives, substantial batch variability, or even those made for a single patient, this question has implications for treatment quality. On November 2, the U.S. Food and Drug Administration (FDA) issued final guidance recommending that companies incorporate potency assurance throughout development, manufacturing, and commercialization.

The guidance, “Potency Assurance for Cellular and Gene Therapy Products,” replaces the January 2011 guidance on potency testing. Here, “potency” refers to a product’s capacity to produce a specific biological effect. It is an important basis for assessing quality, but it cannot be directly equated with the amount of clinical benefit a patient will necessarily receive. The new document focuses on extending the evidence supporting this capacity from early development through the postmarketing period.

The FDA explicitly states in the guidance that lot release testing alone cannot adequately ensure potency. Differences in raw materials, manufacturing processes, and storage conditions all need to be included in the overall assessment. Potency assays should therefore be used not only to determine whether a product can be released, but also in studies of stability, compatibility with administration devices, manufacturing processes, and comparability before and after manufacturing changes, to confirm whether the product maintains the required activity at different stages.

This also means that quality assessments generally cannot rely on a single value. The guidance recommends that strategies generally include multiple release tests to provide evidence on critical quality attributes related to potency that may be affected. The FDA also explains that biological assays do not need to fully replicate a product’s mechanism of action. Assay design must be based on the characteristics and risks of each product, rather than applying the same testing template across products.

For products with short shelf lives, the time required for testing is particularly difficult to reconcile with the time available for use. Viral vector gene therapies and patient-specific therapies also have their own manufacturing and assessment constraints. The FDA’s press release identifies these products as special considerations and emphasizes that controls on raw material variability, in-process testing, and confirmation of each batch’s biological activity should provide mutually supporting evidence of quality.

However, the final guidance does not introduce a new, comprehensive set of legal requirements. The FDA states in the document that this integrated strategy does not add requirements for sponsors. Unless specific laws or regulations are cited, the guidance’s recommendations are not themselves legally binding. Companies must still meet their existing quality obligations, while the document provides a science- and risk-based approach to planning potency assurance.

This update moves the question from “what tests are needed before release” to “how to maintain activity throughout the product lifecycle.” For development teams, the practical implication is to establish evidence early to support manufacturing, storage, and delivery conditions. Whether this approach can shorten development timelines, reduce batch failures, or improve treatment outcomes will require subsequent implementation data and cannot be inferred from the guidance’s publication alone.

References

  1. FDA
  2. FDA